Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals announced the success of its pivotal Phase 2b/3 Saturn-1 trial for TP-03, demonstrating significant outcomes in treating Demodex blepharitis. The trial met all primary and secondary endpoints, with 81% of patients achieving clinically meaningful collarette cures by day 43. Notably, TP-03 showed a good safety profile, with no serious treatment-related adverse events. This is crucial as Demodex blepharitis affects an estimated 25 million Americans and currently lacks FDA-approved therapies. A conference call to discuss detailed results is scheduled for today at 8:00 a.m. ET.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced a webcast and conference call scheduled for June 21, 2021, at 8:00 a.m. ET, to discuss results from the Saturn-1 Phase 2b/3 trial of TP-03 for treating Demodex blepharitis. The event will provide insights into the trial outcomes and a corporate update. TP-03 is a key candidate in Tarsus' pipeline, aimed at addressing high unmet needs in eye care. The company is also developing TP-05 for Lyme disease. Full details will be available on Tarsus' website post-event.

Tarsus Pharmaceuticals has initiated the Phase 1 Callisto trial for TP-05, an oral non-vaccine therapeutic aimed at preventing Lyme disease, which affects over 30 million Americans. The trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. TP-05 utilizes lotilaner, an anti-parasitic agent that targets ticks, potentially stopping the transmission of the Borrelia bacteria. This trial is pivotal, as there are currently no FDA-approved preventative treatments for Lyme disease.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian and CCO Aziz Mottiwala will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The presentation will cover the company’s mission to address unmet medical needs through innovative treatments, particularly in eye care. Tarsus is currently advancing its lead product candidate, TP-03, for Demodex blepharitis and Meibomian Gland Disease. A live webcast and replays will be available on their website.

Tarsus Pharmaceuticals has initiated the Saturn-2 Phase 3 trial for TP-03, targeting Demodex blepharitis, with topline data from Saturn-1 expected in July 2021. The FDA has accepted the IND for TP-05, a potential Lyme disease prevention therapy, with a Phase 1 study planned for July. Financially, the company reported a net income of $10.4 million in Q1 2021, a turnaround from a $2.0 million loss in Q1 2020. License fees from a strategic partnership with LianBio generated $33.4 million in revenue. Cash reserves stand at $156.2 million as of March 31, 2021.

Tarsus Pharmaceuticals (NASDAQ: TARS) has initiated enrollment in the Saturn-2 pivotal trial for TP-03, a novel treatment for Demodex blepharitis, affecting up to 25 million Americans. This follows the successful completion of enrollment in the Saturn-1 trial with 421 participants, with topline results expected this July. TP-03 targets Demodex mites with a topical formulation, and if successful, may lead to the first FDA-approved treatment for this condition. With no current approved therapies, the need for effective solutions is significant.

Tarsus Pharmaceuticals has announced that the FDA accepted its Investigational New Drug (IND) application for TP-05, a novel oral therapy aimed at preventing Lyme disease. This significant milestone allows the company to start a Phase 1 study focusing on safety and pharmacokinetics in July 2021. Lyme disease affects over 300,000 Americans annually, and TP-05 could be the first approved non-vaccine therapeutic. Tarsus is also exploring TP-05 for malaria prevention, while continuing clinical trials for its lead product candidate, TP-03.

Tarsus Pharmaceuticals announced significant findings from the Atlas study, highlighting that Demodex blepharitis affects approximately 25 million Americans, with 80% of patients reporting a negative impact on daily life. Tarsus' lead candidate, TP-03, has shown promising Phase 2b efficacy and safety results, paving the way for pivotal Saturn-1 and Saturn-2 trials. The Europa study confirmed TP-03's effectiveness, achieving an 80% collarette cure rate. Tarsus aims to advance its clinical program, addressing the substantial psychosocial burdens caused by this condition.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that its CEO, Bobak Azamian, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12 at 5:00 PM ET. The presentation aims to provide an overview of Tarsus' innovative approach to eye care and its lead product TP-03, which is in a pivotal Phase 2b/3 trial for treating Demodex blepharitis. Live webcasts will be accessible on their investor relations page and available for 90 days.

For further inquiries, contact SuJin Oh at Shop PR.